Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597682 | 0.77 | ALDH1A1 (0.53) | ALDH1A1KDM4ECYP1A2MEN1KMT2A | |
| SCHEMBL13206625 | 0.71 | MEN1 (0.56) | ALDH1A1KDM4ECYP1A2MEN1KMT2A | |
| SCHEMBL22623757 | 0.71 | MEN1 (0.56) | ALDH1A1KDM4ECYP1A2MEN1KMT2A | |
| SCHEMBL2173695 | 0.71 | MEN1 (0.56) | ALDH1A1KDM4ECYP1A2MEN1KMT2A | |
| SCHEMBL14790130 | 0.70 | ALDH1A1 (0.53) | ALDH1A1KDM4ECYP1A2MEN1KMT2A | |
| SCHEMBL13704044 | 0.69 | GPR3 (0.60) | ALDH1A1KDM4ECYP1A2MEN1KMT2A | |
| SCHEMBL13704120 | 0.69 | GPR3 (0.60) | ALDH1A1KDM4ECYP1A2MEN1KMT2A | |
| SCHEMBL22792110 | 0.69 | GPR3 (0.60) | ALDH1A1KDM4ECYP1A2MEN1KMT2A | |
| SCHEMBL7635143 | 0.67 | KDM4E (0.46) | ALDH1A1KDM4ECYP1A2MEN1KMT2A | |
| SCHEMBL14579466 | 0.67 | ALDH1A1 (0.50) | ALDH1A1KDM4ECYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034939-B2 | 1-{3-H-imidazo[4,5-c]pyridin-2-yl}-3,4-dihydro-2H-pyrido[2,1-a] isoindole-6-one; anticarcinogenic agent: solid tumor and leukemia; neurodegenerative diseases: Alzheimer's and Huntington's diseases | AVENTIS PHARMA S.A.. (FR) | 2011-10-11 | — | — | US | disclosed |
| US-8034939-B2 | 1-{3-H-imidazo[4,5-c]pyridin-2-yl}-3,4-dihydro-2H-pyrido[2,1-a] isoindole-6-one; anticarcinogenic agent: solid tumor and leukemia; neurodegenerative diseases: Alzheimer's and Huntington's diseases | AVENTIS PHARMA S.A.. (FR) | 2011-10-11 | — | — | US | disclosed |
| EP-1869042-B1 | NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF IN PARTICULAR AS INHIBITORS OF CHAPERONE PROTEIN HSP90 ACTIVITIES | AVENTIS PHARMA SA (FR) | 2011-02-02 | — | — | EP | disclosed |
| US-20080119507-A1 | Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities | AVENTIS PHARMA S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| US-20080119507-A1 | Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities | AVENTIS PHARMA S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119507-A1 | Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities | HSP90B1, HSP90AB2P, HSP90AB1 | ALDH1A1 1204/4885KDM4E 4283/4885CYP1A2 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.